Summary
This is a parallel arm study to evaluate AGS-8M4 administered in combination with chemotherapy in subjects with ovarian cancer. AGS-8M4 will be administered as an IV infusion until disease worsens.
Key Facts
Lead Sponsor
Enrollment
Start Date
Completion Date
Study Type
Official Title
Interventions
Conditions
Eligibility
Age Range
Sex
Inclusion Criteria: * Subjects with recurrent disease Stage III/IV diagnosis of epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal carcinoma * Subjects with either platinum resistant or platinum sensitive ovarian cancer * At least 14 days of previous cytotoxic chemotherapy and have recovered from all toxicities * Left ventricular ejection fraction (LVEF) equal to or greater than the institutional lower limit of normal as measured by echocardiogram or MUGA (ONLY required for platinum resistant patients) Exclusion Criteria: * Active infection requiring treatment with systemic (intravenous or oral) anti-infectives (antibiotic, antifungal, or antiviral agent) within 72 hours of screening * Use of any investigational drug within 30 days prior to screening * Prior monoclonal antibody therapy other than Avastin * Avastin administration within 90 days of screening * History of thromboembolic events and bleeding disorders ≤ 3 months (e.g.,DVT or PE)